China Inc. Eyes Gene Therapy In Post-Coronavirus Growth Trajectory
Large Patient Pool An Advantage?
Eyeing a largely untapped treatment area and huge patient pool, biotechs in China are leaping into the gene therapy foray despite the lack of a distinct regulatory pathway or reimbursement of the highly costly treatments.
You may also be interested in...
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
China's latest national census data paint a mixed picture for the provision of health in the world’s most populous nation, with multiple major trends potentially impacting areas of opportunity.
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.